The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.
India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.
The South Korean market is characterized by its aging population and an affluent population. Growth potential is limited as it has evolved to a developed market and industry players expect it to have established regulations.
India has enforced stricter patent laws compared to other countries. For a drug to be patentable in India, the invention has to be novel, inventive, and industrially applicable.
After a series of government reforms, the Japanese pharma market is making a comeback.